magnetic flow cytometry

Additional Info

  • Overview:

    Namdiatream Grant



    Co-ordinator          Prof. Yuri Volkov, Trinity College Dublin, Ireland.
    Academic:  Trinity College Dublin, nanoGUNE, Austrian Institute of Technology, Universite de GenevePhilipps Universität Marburg, University College Dublin, INSERM (ATI, U624 Marseille), Institut National des Sciences Appliquées de Toulouse (INSAT), Technical University BraunSchweigEcole Polytechnique Federale de Lausanne (ISIC),  Universite de Savoie Polytech'Savoie, MPG Max-Planck-Gesellschaft zur Forderung der Wissenschaft e.VGottingen.
    Industrial:  Cellix Ltd, BD Biosciences, Nikon Instruments, Progenika Biopharma S.A., Selective Antibodies Ltd., NanoSight Ltd., Radisense Diagnostics Ltd., Advanced Accelerator Applications, Forschungsinstitut für mineralische und metallische WerkstoffeEdelsteine/Edelmetalle GmbH, INNOVA S.p.A.
    Funding Body EU Commission
    Grant Type Large scale integrating (FP7)
    Date 1 July 2010 – 30 June 2014
    Total Grant Amount €12,000,000
    Keywords magnetic barcode, nanowires, cancer biomarkers, diagnostics
    Contact This email address is being protected from spambots. You need JavaScript enabled to view it. or phone +353-1-4500-1550
    Project Website

    Cellix's contribution to NAMDIATREAM grant:

    Cellix is involved in Platform 4 of this grant working with Trinity College Dublin, Radisens and BD Biosciences to develop a clinically relevant prototype instrument based on a magnetic barcode system (encoding, reading, multiplexing & screening) for the detection of cancer biomarkers.
    Overall Project Aims:
    NAMDIATREAM will develop a cutting edge nanotechnology-based tool kit for multi-modal detection of biomarkers of most common cancer types and cancer metastases, permitting identification of cells indicative of early disease onset in a high-specificity and throughput format in clinical, laboratory and point-of-care devices. The project is built on the innovative concepts of super-sensitive and highly specific lab-on-a-bead , lab-on-a-chip and lab-on-a-wire nano-devices utilizing photo-luminescent, plasmonic, magnetic and non-linear optical properties of nano-materials. This offers ground-breaking advantages over present technologies in terms of stability, sensitivity, time of analysis, probe multiplexing, assay miniaturisation and reproducibility. The ETP in nano-medicine documents point out that nanotechnology has yet to deliver practical solutions for the patients and clinicians in their struggle against common, socially and economically important diseases such as cancer.

    Over 3.2M new cases and 1.7M cancer-related deaths are registered in Europe every year, largely because diagnostic methods have an insufficient level of sensitivity, limiting their potential for early disease identification. We will deliver Photo-luminescent nano-particle-based reagents and diagnostic chips for high throughput early diagnosis of cancer and treatment efficiency assessment Nano-crystals enabling plasmon-optical and nonlinear optical monitoring of molecular receptors within body fluids or on the surface of cancer cell Multi-Parameter screening of cancer biomarkers in diagnostic material implementing segmented magnetic nano-wires Validation of nano-tools for early diagnosis and highly improved specificity in cancer research. OECD-compliant nano-materials with improved stability, signal strength and biocompatibility Direct lead users of the results will be the diagnostic and medical imaging device companies involved in the consortium, clinical and academic partners.
  • Recommended Products:

    ExiGo Pump and biochips for flow focusing

    ExiGo - iPad mini or LabVIEW controlled Microfluidic Pump
    The ExiGo™ pump is a microfluidic syringe pump controlled...

    VenaDeltaY1 and VenaDeltaY2
    The VenaDeltaY1™ and VenaDeltaY2™ biochips contain...